Circulating endogenous cannabinoid anandamide and portal, systemic and renal hemodynamics in cirrhosis

Liver International

Volumn 24, Issue 5, 2004, Pages 477-483

  Fernández Rodriguez, Conrado M ^a   Romero, Julian ^b   Petros, Timothy J ^b   Bradshaw, Heather ^b   Gasalla, José M ^a   Gutiérrez, Maria Luisa ^a   Lledó, José L ^a   Santander, Cecilio ^a   Pérez Fernández, Teresa ^a   Tomás, Esperanza ^a   Cacho, Guillermo ^a   Walker, J Michael ^b  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^b BROWN UNIVERSITY   (United States)

Author keywords

Endocannabinoids; Hemodynamic disturbance of cirrhosis

Indexed keywords

ANANDAMIDE; ENDOCANNABINOID; AMIDE; ARACHIDONIC ACID DERIVATIVE;

ADULT; ARTICLE; ASCITES; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEMODYNAMIC MONITORING; HUMAN; KIDNEY DYSFUNCTION; LIVER CIRRHOSIS; LIVER DYSFUNCTION; MALE; PORTAL HYPERTENSION; VASODILATATION; BLOOD; GLOMERULUS FILTRATION RATE; HEART STROKE VOLUME; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; VASCULAR RESISTANCE;

ARACHIDONIC ACIDS; ENDOCANNABINOIDS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION, PORTAL; LIVER CIRRHOSIS; MALE; MIDDLE AGED; POLYUNSATURATED ALKAMIDES; STROKE VOLUME; VASCULAR RESISTANCE;

EID: 16644390376     PISSN: 14783223     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2004.0945.x     Document Type: Article

References (39)

1. Groszman R J. Hyperdynamic circulation of liver disease 40 years later: pathophysiology and clinical consequences. Hepatology 1994; 20: 1359-63.
2. Martin P Y, Schrier R W. Pathogenesis of water and sodium retention in cirrhosis. Kidney Int Suppl 1997; 59: S43-49.
3. Ginès P, Fernández-Esparrach G, Arroyo V, Rodes J. Pathogenesis of ascites in cirrhosis. Semin Liver Dis 1997; 17: 175-89.
4. Shapiro M D, Nicholls K M, Groves B M, Kluge R, Chung H M, Bichet D G, et al. Interrelationship between cardiac output and vascular resistance as determinants of effective arterial blood volume in cirrhotic patients. Kidney Int 1985; 2: 206-11.
5. Llach J, Gines P, Arroyo V, Rimola A, Titó L, Badalamenti S, et al. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology 1988; 94: 482-7.
6. Martin P Y, Gines P, Schrier R W. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med 1998; 20339: 533-41.
7. Martin P Y, Ohara M, Gines P, Xu D L, St John J, Niederberger M, et al. Nitric oxide synthase (NOS) inhibition for one week improves renal sodium and water excretion in cirrhotic rats with ascites. J Clin Invest 1998; 101: 235-42.
8. Iwakiri Y, Cadelina G, Sessa W C, Groszmann R J. Mice with targeted gene deletion of eNOS develop the hyperdynamic circulation associated with portal hypertension. Am J Physiol Gastrointest Liver Physiol 2002; 283: G1074-81.
9. Batkai S, Jarai Z, Wagner J A, Goparaju S K, Varga K, Liu J, et al. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med 2001; 7: 827-32.
10. Ros J, Claria J, To-Figueras J, Planaguma A, Cejudo-Martin P, Fernandez-Varo G, et al. Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. Gastroenterology 2002; 122: 85-93.
11. Chaytor AT, Martin P E, Evans W H, Randall M D, Griffith T M. The endothelial component of cannabinoid-induced relaxation in rabbit mesenteric artery depends on gap junctional communication. J Physiol 1999; 520: 539-50.
12. Liu J, Gao B, Mirshahi F, Sanyal A J, Khanolkar A D, Makriyannis A L, et al. Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem J 2000; 15346: 835-40.
13. Hillard C. Endocannabinoids and vascular function. J Pharmacol Exp Therap 2000; 294: 27-32.
14. Randall M D, Kendall D A. Anandamide and endothelium-derived hyperpolarizing factor act via a common vasorelaxant mechanism in rat mesentery. Eur J Pharmacol 1998; 346: 51-3.
15. Zygmunt P M, Petersson J, Andersson D A, Chuang H, Sorgard M, Di Marzo, et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 1999; 400: 452-7.
16. Fleming I, Schermer B, Popp R, Busse R Inhibition of the production of endothelium-derived hyperpolarizing factor by cannabinoid receptor agonists. Br J Pharmacol 1999; 126: 949-60.
17. Offertaler L, Mo F M, Batkai S, Liu J, Begg M, Razdan R K, et al. Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Mol Pharmacol 2003; 63: 699-705.
18. Pugh R N, Murray-Lyon I M, Dawson J L, Pietroni M C, Williams R, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-9.
19. Labovitz A J, Buckingham T A, Habermehl K, Nelson J, Kennedy H L, Williams G A. The effects of sampling site on the two-dimensional echo-Doppler determination of cardiac output. Am Heart J 1985; 109: 327-32.
20. McLennan F M, Haites N E, Mackenzie J D, Daniel M K, Rawles J M. Reproducibility of linear cardiac output measurement by Doppler ultrasound alone. Br Heart J 1986; 55: 25-31.
21. Julius S. Validation of non-invasive measurement of cardiac output. The Ann Arbor experience. Eur Heart J 1990; 11: 144-7.
22. Christensen A B, Groth S. Determination of 99mTc-DTPA clearance by a single plasma sample method. Clin Physiol 1986; 6: 579-88.
23. Perrone R D, Steinman T I, Beck G J, Skibinski C I, Royal H D, Lawlor M, et al. Utility of radioisotopic filtration markers in chronic renal insufficiency: simultaneous comparison of 125I-iothalamate, 169Yb-DTPA, 99mTc-DTPA, and inulin. The Modification of Diet in Renal Disease Study. Am J Kidney Dis 1990; 16: 224-35.
24. Chachati A, Meyers A, Rigo P, Godon J P. Validation of a simple isotopic technique for the measurement of global and separated renal function. J Uremia Invest 1985-1986; 9: 177-9.
25. Grisham M B, Johnson G G, Lancaster J R Jr. Quantitation of nitrate and nitrite in extracellular fluids. Methods Enzymol 1996; 268: 237-46.
26. Walker J M, Huang S M, Stangman N M, Tsou K, Sañudo-Peña M C. Pain modulation by release of the endogenous cannabinoid anandamide. Proc Natl Acad Sci 1999; 96: 12198-203.
27. Bisogno T, De Petrocellis L, Di Marzo V. Fatty amide hydrolase, an enzyme with many bioactive substrates. Possible Therapeutic Implications. Curr Pharmaceuti Des 2002; 8: 125-33.
28. Deutsch D G, Glaser S T, Howell J M, Kunz J S, Puffenbarger R A, Hillard C, et al. The cellular uptake of anandamide is coupled to its breakdown by fatty-acid amide hydrolase. J Biol Chem 2001; 276: 6967-73.
29. Maccarrone M, Bari M, Menichelli A, Giuliani E, Del Principe D, Finazzi-Agro A. Human platelets bind and degrade 2-arachidonoylglycerol, which activates these cells through a cannabinoid receptor. Eur J Biochem 2001; 268: 819-25.
30. Maccarrone M, Fiorucci L, Erba F, Bari M, Finazzi-Agro A, Ascoli F. Human mast cells take up and hydrolyze anandamide under the control of 5-lipoxygenase and do not express cannabinoid receptors. FEBS Lett 2000; 468: 176-80.
31. Maccarrone M, De Petrocellis L, Bari M, Fezza F, Salvati S, Di Marzo V. Lipopolysaccharide downregulates fatty acid amide hydrolase expression and increases anandamide levels in human peripheral lymphocytes. Arch Biochem Biophys 2001; 393: 321-8.
32. Bauer T M, Schwacha H, Steinbruckner B, Brinkmann F E, Ditzen A K, Aponte J J. Small intestinal bacterial overgrowth in human cirrhosis is associated with systemic endotoxemia. Am J Gastroenterol 2002; 97: 2364-70.
33. Albillos A, de la Hera A, González M, Moya J L, Calleja J L, Montserrat J, et al. Increased lipopolysaccharide binding protein in ncirrhostic patients with marked immune and hemodynamic derangement. Hepatology 2003; 37: 208-17.
34. Campillo B, Bories P N, Benvenuti C, Dupeyron C. Serum and urinary nitrate levels in liver cirrhosis: endotoxemia, renal function and hyperdynamic circulation. J Hepatol 1996; 24: 707-14.
35. Genescá J, Gonzalez A, Segura R, Caltalan R, Marti R, Varela E, et al. Interleukin-6, nitric oxide, and the clinical and hemodynamic alterations of patients with liver cirrhosis. Am J Gastroenterol 1999; 94: 169-77.
36. Valeriano V, Funaro S, Lionetti R, Riggio O, Pulcinelli G, Fiore P, et al. Modification of cardiac function in cirrhotic patients with and without ascites. Am J Gastroenterol 2000; 95: 3200-5.
37. Guarner C, Soriano G, Tomas A, Bulbena O, Novella M T, Balanzo J, et al. Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia. Hepatology 1993; 18: 1139-43.
38. Garcia-Tsao G, Angulo P, Garcia J C, Groszmann R J, Cadelina G W. The diagnostic and predictive value of ascites nitric oxide levels in patients with spontaneous bacterial peritonitis. Hepatology 1998; 1: 17-22.
39. Ellis A, Wendon J. Circulatory, respiratory, cerebral, and renal derangements in acute liver failure: pathophysiology and management. Semin Liver Dis 1996; 16: 379-88.